TrialThe oncologist2011

Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.

Miguel Nogué et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.